TOLL样受体9/激活蛋白-1信号通路在过敏性鼻炎中的作用

The role and mechanism of TLR9/AP-1 signal pathway in allergic rhinitis

目的探讨TOLL样受体9/激活蛋白-1(TLR9/AP-1)信号通路在过敏性鼻炎中的作用机制。方法48只SD大鼠采用随机数字表法分为对照组、实验组、干预组,每组16只。实验组、干预组制备过敏性鼻炎大鼠的动物模型。干预组造模成功后给予治疗药物干预。将各组16只大鼠采用随机数字表法分为两组,每组8只,分别于末次干预后6、12 h处死后采集血液标本和鼻黏膜标本。检测各组大鼠干预后免疫球蛋白E(IgE)、白细胞介素-4(IL-4)、肿瘤坏死因子-α(TNF-α)、症状评分、鼻黏膜组织中C-Fos、C-Jun表达。结果实验组大鼠IgE[(18.65±1.09)IU/mL比(11.39±1.56)IU/mL]、IL-4[(75.33±7.16)ng/L比(56.55±6.08)ng/L]、TNF-α[(57.25±5.15)ng/L比(32.33±2.26)ng/L]、症状评分、C-Fos[(0.850±0.012)比(0.425±0.050)]、C-Jun[(0.950±0.052)比(0.425±0.030)]均明显高于对照组,差异有统计学意义(P<0.01)。干预组大鼠IgE[(15.95±1.02)IU/mL]、IL-4[(65.12±5.47)ng/L]、TNF-α[(48.53±4.18)ng/L]、症状评分、C-Fos[(0.575±0.047)]、C-Jun[(0.615±0.047)]均明显低于实验组,差异有统计学意义(P<0.01)。结论药物治疗过敏性鼻炎的机制与抑制TLR9/AP-1信号通路及其下游因子的释放和分泌有关。

Objective To explore the role and mechanism of TLR9/AP-1 signal pathway in allergic rhinitis.Methods Forty-eight SD rats were divided into control group,experimental group and intervention group,with 16 rats in each group.Animal models of allergic rhinitis were prepared in the experimental group and the intervention group.The intervention group was given therapeutic drug intervention after successful modeling.Sixteen rats in each group were randomly divided into two groups(8 rats in each group),and blood samples and nasal mucosa samples were collected after 6h and 12h after the last intervention,respectively.The expression of IgE,IL-4,TNF-a,symptom score,C-Fos and C-Jun in nasal mucosa were detected.Results IgE[(18.65±1.09)IU/mL vs.(11.39±1.56)IU/mL],IL-4[(75.33±7.16)ng/L vs.(56.55±6.08)ng/L],TNF-α[(57.25±5.15)ng/L vs.(32.33±2.26)ng/L],symptom score,C-Fos[(0.850±0.012)vs.(0.425±0.050)]and C-Jun[(0.950±0.052)vs.(0.425±0.030)]in the experimental group were significantly higher than those in the control group,with statistically significant differences(P<0.01).In the intervention group,IgE[(15.95±1.02)IU/mL],IL-4[(65.12±5.47)ng/L],TNF-α[(48.53±4.18)ng/L],symptom score,C-Fos[(0.575±0.047)]and C-Jun[(0.615±0.047)]were significantly lower than those in the experimental group,with statistically significant differences(P<0.01).Conclusion The mechanism of drug therapy for allergic rhinitis is related to the inhibition of TLR9/AP-1 signaling pathway and the release and secretion of downstream factors.